Literature DB >> 15158784

A novel 3D-QSAR comparative molecular field analysis (CoMFA) model of imidazole and quinazolinone functionalized p38 MAP kinase inhibitors.

Gilberto M Sperandio da Silva1, Carlos M R Sant'Anna, Eliezer J Barreiro.   

Abstract

In this study we describe a new comparative molecular field analysis (CoMFA) model of dihydroquinazolinone and tetrasubstituted imidazole compounds with p38 MAPK inhibitory activity. A series of 51 (a training set of 40 and a test set of 11) dihydroquinazolinone [Bioorg. Med. Chem. Lett. 2003, 13, 277.] and tetrasubstituted imidazole [J. Med. Chem. 1999, 42, 2180.] derivatives known as p38 mitogen-activated protein kinase (p38 MAPK) selective inhibitors was studied by quantitative structure-activity relationship (3D-QSAR) analysis using comparative molecular field analysis. The 3D-QSAR models were generated and evaluated by a scheme that combines a genetic algorithm (GA) optimization with partial least squares (PLS) regression and by crossvalidation using the leave-one-out technique. The model was able to efficiently predict the activities of the compounds of the test set, suggesting that it can be used for the planning of new p38 MAPK inhibitor candidates useful to treat chronic inflammatory states.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15158784     DOI: 10.1016/j.bmc.2004.04.004

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

1.  Structural requirements of N-substituted spiropiperidine analogues as agonists of nociceptin/orphanin FQ receptor.

Authors:  Pingping Bao; Xiaole Zhang; Hong Ren; Yan Li; Zulin Mu; Shuwei Zhang; Guohui Li; Ling Yang
Journal:  Int J Mol Sci       Date:  2011-12-06       Impact factor: 5.923

2.  Insight into the Structural Determinants of Imidazole Scaffold-Based Derivatives as TNF-α Release Inhibitors by in Silico Explorations.

Authors:  Yuan Wang; Mingwei Wu; Chunzhi Ai; Yonghua Wang
Journal:  Int J Mol Sci       Date:  2015-08-25       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.